CVS Health Corp. announced on Jan. 3 that it would remove Humira (adalimumab) from CVS Caremark’s major national commercial template formularies and cover the drug’s biosimilars, effective April 1. The PBM said customers with Choice and Standard Opt Out commercial formularies would continue to have an option to have Humira on their formularies. CVS also noted that AbbVie, which manufactures Humira, will supply a co-branded adalimumab biosimilar to Cordavis, a wholly owned CVS biosimilar-focused subsidiary that launched this year. Nearly 90% of Caremark’s 25.3 million commercial pharmacy lives currently have preferred access to Humira, largely with utilization management restrictions applied.
SOURCE: MMIT Analytics, as of 1/8/24